US Patent

US9220694 — Emulsion compositions containing cetalkonium chloride

Formulation · Assigned to Santen SAS · Expires 2026-01-27 · 0y expired

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects emulsion compositions containing cetalkonium chloride, specifically those with certain quaternary compounds and ammonium halides.

USPTO Abstract

Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

Drugs covered by this patent

Patent Metadata

Patent number
US9220694
Jurisdiction
US
Classification
Formulation
Expires
2026-01-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Santen SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.